Signal Detection in EUROmediCAT: Identification and Evaluation of Medication–Congenital Anomaly Associations and Use of VigiBase as a Complementary Source of Reference-Reference-Cited by-同舟云学术

Signal Detection in EUROmediCAT: Identification and Evaluation of Medication–Congenital Anomaly Associations and Use of VigiBase as a Complementary Source of Reference

Published:2021-05-09 Issue: Volume: Page:
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Cavadino Alana^ORCID,Sandberg Lovisa^ORCID,Öhman Inger^ORCID,Bergvall Tomas^ORCID,Star Kristina^ORCID,Dolk Helen,Loane Maria^ORCID,Addor Marie-Claude,Barisic Ingeborg,Cavero-Carbonell Clara,Garne Ester^ORCID,Gatt Miriam,Khoshnood Babak,Klungsøyr Kari^ORCID,Latos-Bielenska Anna,Lelong Nathalie,Lutke Reneé,Materna-Kiryluk Anna,Nelen Vera,Nevill Amanda,O’Mahony Mary,Mokoroa Olatz,Pierini Anna,Randrianaivo Hanitra,Rissmann Anke^ORCID,Tucker David,Wiesel Awi,Yevtushok Lyubov^ORCID,Morris Joan K^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

https://link.springer.com/content/pdf/10.1007/s40264-021-01073-z.pdf

Reference66 articles.

1. Lupattelli A, Spigset O, Twigg MJ, Zagorodnikova K, Mardby AC, Moretti ME, et al. Medication use in pregnancy: a cross-sectional, multinational web-based study. BMJ Open. 2014;4(2):e004365.

2. Engeland A, Bjørge T, Klungsøyr K, Hjellvik V, Skurtveit S, Furu K. Trends in prescription drug use during pregnancy and postpartum in Norway, 2005 to 2015. Pharmacoepidemiol Drug Saf. 2018;27(9):995–1004.

3. Bérard A, Abbas-Chorfa F, Kassai B, Vial T, Nguyen KA, Sheehy O, et al. The French Pregnancy Cohort: Medication use during pregnancy in the French population. PLoS ONE. 2019;14(7):e0219095.

4. Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet. 2011;157(3):175–82.

5. Caton AR, Bell EM, Druschel CM, Werler MM, Lin AE, Browne ML, et al. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension (Dallas, Tex: 1979). 2009;54(1):63-70.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrase inhibitor drugs during pregnancy and congenital anomalies: A case/non‐case study from the global pharmacovigilance database VigiBase®;Pharmacology Research & Perspectives;2024-07-31

2. PANORAMA DOS FATORES TERATOGÊNICOS QUE OCASIONAM O SURGIMENTO DAS CARDIOPATIAS CONGÊNITAS: UMA REVISÃO SISTEMÁTICA;Revista Contemporânea;2024-05-23

3. In-Depth Genomic Analysis: The New Challenge in Congenital Heart Disease;International Journal of Molecular Sciences;2024-02-01

4. Detection of potential safety signals related to the use of remdesivir and tocilizumab in the COVID era during pregnancy, resorting to open data from the FDA adverse event reporting system (FAERS);Frontiers in Pharmacology;2024-01-31

5. Detection and evaluation of signals associated with exposure to individual and combination of medications in pregnancy: a signal detection study protocol;BMJ Open;2023-10